Financing worries and rivals disrupted Pfizer's courting of Wyeth
This article was originally published in Scrip
Executive Summary
The path towards Pfizer's $68 billion acquisition of Wyeth was littered with financing hurdles and the emergence of an unknown rival called "Company X", a regulatory filing has shown. Talks between the firms stalled continuously as the unravelling financial crisis crippled the debt markets.